After SARS-COV-2 virus enters the human body, B cells will produce different types of antibodies. In the early stage of infection (7 days of initial illness), the human body will produce IgA and IgM antibodies, but they can only survive in the body for about 30 days. IgG antibodies are produced late, but they can stay in the body for several months. At the same time, the titers of IgG antibodies in the recovery phase are several times higher than the gradient in the acute infection phase. Therefore, the detection of SARS-CoV-2 IgG/IgM (IgA) can be used for disease course monitoring, epidemiological investigation, and large-scale preliminary screening. For the detection of different types of antibodies, the process and stage of the disease can be distinguished. The N protein (prokaryotic expression), the S1 protein (eukaryotic expression), the RBD protein (eukaryotic expression), mouse anti-human IgG monoclonal antibody, mouse anti-human IgM monoclonal antibody, mouse Anti-human IgA monoclonal antibody can be used for SARS-COV-2 IgG, IgM, IgA antibody typing detection, with high sensitivity and high specificity. Good antigen/antibody can greatly improve the accuracy of detection reagents. As the virus continues to mutate, Biomapper has designed and developed antigens for different immune strains to respond to different mutant strains at any time. At the same time, Biomapper has also developed two sufficient proteins (N protein and S protein) for the positive quality control of new crown antigen detection.